Scarica l'app Stockscreener
69.97
0.43%
-0.30
Precedente Chiudi:
$70.27
Aprire:
$70
Volume 24 ore:
1.69M
Relative Volume:
0.70
Capitalizzazione di mercato:
$11.15B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-23.02
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
+1.19%
1M Prestazione:
+9.33%
6M Prestazione:
+161.96%
1 anno Prestazione:
+84.37%
Intervallo 1D:
$69.40
$70.49
Intervallo di 1 settimana:
$67.95
$71.87
Portata 52W:
$23.95
$71.87
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
69.97 | 11.20B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
News impact scoring models applied to Ionis Pharmaceuticals Inc.Bull Run & AI Based Buy and Sell Signals - newser.com
Can you recover from losses in Ionis Pharmaceuticals Inc.Gap Up & Reliable Entry Point Trade Alerts - newser.com
Ionis Pharmaceuticals Hits New 52-Week High of $71.87 - Markets Mojo
Can technical indicators confirm Ionis Pharmaceuticals Inc.’s reversalProduct Launch & Safe Entry Trade Signal Reports - newser.com
Will Ionis Pharmaceuticals Inc. price bounce be sustainableIndex Update & Fast Momentum Entry Tips - newser.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Recent Milestones Are Shaping the Outlook and Valuation for Ionis Pharmaceuticals - Yahoo Finance
A Look at Ionis Pharmaceuticals's Valuation Following Pipeline Progress and Strong Innovation Day Updates - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $78.00 at Needham & Company LLC - MarketBeat
Eric Swayze Sells 6,849 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $937,375.34 in Stock - MarketBeat
Brett Monia Sells 437 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Poised To Break Even In 2028 Fueled By A Cadence Of Launches - insights.citeline.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on pipeline strength - Investing.com Nigeria
Ionis Pharmaceuticals EVP Swayze sells $472k in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (NASDAQ:IONS) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Castle Rock Wealth Management LLC Invests $215,000 in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by DAVENPORT & Co LLC - MarketBeat
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP O’Neil sells $937k in IONS stock By Investing.com - Investing.com South Africa
Ionis Pharma EVP Baroldi sells $112k in shares By Investing.com - Investing.com Canada
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Ionis Pharmaceuticals EVP O’Neil sells $937k in IONS stock - Investing.com Nigeria
Oppenheimer Maintains Ionis Pharmaceuticals (IONS) Outperform Recommendation - Nasdaq
Ionis Pharma EVP Baroldi sells $112k in shares - Investing.com India
Ionis Pharmaceuticals EVP Swayze sells $472k in stock - Investing.com India
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Pharmaceuticals stock hits 52-week high at 70.49 USD By Investing.com - Investing.com Nigeria
Needham Raises Price Target on Ionis Pharmaceuticals (IONS) to $78 | IONS Stock News - GuruFocus
Oppenheimer Raises Ionis Pharmaceuticals (IONS) Price Target to $90 | IONS Stock News - GuruFocus
JP Morgan Boosts Ionis Pharmaceuticals (IONS) with Upgrade and P - GuruFocus
Ionis upgraded at JP Morgan on expanding Tryngolza market, pipeline - Seeking Alpha
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook - FinancialContent
Is Ionis Pharmaceuticals Inc ISI a good long term investmentMid Cap Growth Trends & Discover Strategies with Fellow Traders - earlytimes.in
JP Morgan Upgrades Ionis Pharmaceuticals (IONS) to Overweight, R - GuruFocus
Retinitis Pigmentosa Pipeline 2025: Comprehensive Clinical - openPR.com
HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Overweight at JPMorgan Chase & Co. - MarketBeat
JPMorgan Upgrades Ionis Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $80 From $49 - MarketScreener
HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (I - GuruFocus
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day - BioSpace
Ionis Pharmaceuticals Hits New 52-Week High of $70.14 - Markets Mojo
Transcript : Ionis Pharmaceuticals, Inc.Shareholder/Analyst Call - MarketScreener
Ionis Pharmaceuticals : IONS Innovation Day 2025 FINAL - MarketScreener
Ionis outlines growth strategy with four launches planned by 2026 - Investing.com Nigeria
Ionis Pharmaceuticals Hits New 52-Week High of $69.25 - Markets Mojo
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 12-Month HighHere's What Happened - MarketBeat
Ionis Pharmaceuticals (IONS): Stifel Raises Price Target to $67 - GuruFocus
Published on: 2025-10-06 08:01:09 - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosNew Guidance & Smart Investment Allocation Insights - newser.com
Using fundamentals and technicals on Ionis Pharmaceuticals Inc.July 2025 Breakouts & Safe Capital Growth Tips - newser.com
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ionis Pharmaceuticals Inc Azioni (IONS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| O'NEIL PATRICK R. | EVP CLO & General Counsel |
Oct 06 '25 |
Option Exercise |
52.87 |
10,200 |
539,274 |
67,330 |
| O'NEIL PATRICK R. | EVP CLO & General Counsel |
Oct 06 '25 |
Sale |
69.74 |
13,441 |
937,338 |
53,889 |
| Monia Brett P | Chief Executive Officer |
Oct 06 '25 |
Sale |
69.26 |
437 |
30,268 |
179,572 |
| Baroldi Joseph | EVP, Chief Business Officer |
Oct 06 '25 |
Sale |
69.37 |
1,625 |
112,725 |
30,301 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):